Royalty Pharma plc (RPRX) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Royalty Pharma’s revenue went from $1.8B in fiscal 2018 to $2.4B in fiscal 2025, growth of about 4.1% a year.
Net income in fiscal 2025 was $771M, a net margin of 32.4%; the best year in this period was 2019 with $2.3B.
Over the twelve months to September 30, 2026, revenue was $2.6B and net income $672M.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.4B | $2.3B | $2.4B | $2.2B | $2.3B | $2.1B | $1.8B | $1.8B |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Operating income | $1.5B | $1.6B | $1.3B | $1.5B | $307M | $1.4B | $1.6B | $2.6B | $1.4B |
| Net income | $672M | $771M | $859M | $1.1B | $43M | $620M | $975M | $2.3B | $1.4B |
| EPS (diluted) | $1.53 | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 | — | — |
| R&D | $251M | $452M | $2M | $52M | $177M | $200M | $26M | $83M | $393M |
| Revenue growth | — | +5.1% | −3.9% | +5.2% | −2.3% | +7.9% | +17.0% | +1.1% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.0B | $2.5B | $2.8B | $3.0B | $2.1B | $2.0B | $2.0B | $1.7B | $1.6B |
| Capital spending | — | — | — | — | — | — | — | — | — |
| Free cash flow | $3.0B | — | — | — | — | — | — | — | — |
| Dividends paid | $409M | $378M | $376M | $358M | $333M | $285M | $112M | — | — |
| Buybacks | $262M | $1.2B | $230M | $305M | $0 | $0 | $0 | $4M | $0 |
| Stock-based pay | $460M | $290M | $2M | $2M | $2M | $2M | $5M | $0 | $0 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $637M | $987M | $495M | $1.7B | $1.6B | $1.1B | $246M | $1.9B |
| Debt | — | $9.0B | $7.6B | $6.1B | $7.1B | $7.1B | $5.8B | $6.2B | — |
| Equity | — | $9.7B | $10.3B | $10.1B | $9.5B | $10.2B | $9.9B | $6.1B | $4.6B |
| Total assets | — | $19.6B | $18.2B | $16.4B | $16.8B | $17.5B | $16.0B | $12.4B | — |
| Shares (diluted) | 557M | 564M | 594M | 603M | 438M | 415M | 375M | — | — |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | 57.1% | 65.6% | 57.1% | 63.4% | 13.7% | 62.5% | 75.2% | 144.6% | 76.0% |
| Net margin | 25.7% | 32.4% | 38.0% | 48.2% | 1.9% | 27.1% | 45.9% | 129.4% | 76.8% |
| FCF margin | 113.1% | — | — | — | — | — | — | — | — |
| ROIC | — | 8.3% | 7.2% | 9.2% | 1.8% | 8.2% | 10.2% | 21.2% | 30.0% |
| ROE | — | 7.9% | 8.3% | 11.2% | 0.4% | 6.0% | 9.8% | 38.2% | 30.3% |
Frequently asked questions
What is Royalty Pharma’s annual revenue?
$2.4B in fiscal 2025 and $2.6B over the twelve months to September 30, 2026.
How much profit does Royalty Pharma make?
Net income was $771M in fiscal 2025 (net margin 32.4%).
Is Royalty Pharma’s revenue growing?
Yes: revenue rose 5.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.